RIGEL PHARMACEUTICALS INC cotiza a 47.14 USD y tiene una capitalización bursátil de $872M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytop…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $0.88 | $0.44 | $1.12 |
| Estimado | $0.89 | $-0.08 | $0.87 | $1.20 |
| Sorpresa | — | +1200.0% | -49.4% | -6.7% |
| Métrica | RIGL | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 93.3% | 57.0% | +36.3% |
| Operating Margin | 42.6% | -38.6% | +81.3% |
| Net Margin | 124.7% | -33.6% | +158.3% |
| FCF Margin | — | -13.9% | — |
| ROE | 93.8% | -40.4% | +134.2% |
| ROA | 71.5% | -32.0% | +103.5% |
| Current Ratio | 2.42 | 2.84 | -0.42 |
| Debt / Equity | 0.13 | 0.28 | -0.15 |